Advances in Barrett’s Esophagus: Screening, Surveillance, and Endoscopic Eradication Strategies
Digestive Disease Interventions · 23.06.2026
DOI: 10.1055/a-2879-9369 ↗Kurz gefasst
Fachartikel in der Zeitschrift Digestive Disease Interventions, erschienen am 23.06.2026. Verfasst von Geethanjali M. Rajagopal und 2 weiteren Autor:innen.
Abstract (Originalsprache)
AbstractBarrett's esophagus (BE) is a precursor to esophageal adenocarcinoma, which is associated with poor survival when diagnosed at advanced stages. Early detection and treatment of dysplasia improve outcomes. This review summarizes current strategies for BE screening, surveillance, and management, emphasizing advances in endoscopic diagnosis and therapy. Risk-based screening with esophagogastroduodenoscopy and systematic biopsies remains the diagnostic standard, while emerging nonendoscopic cell collection devices with biomarker assays may expand screening. Management is guided by histologic grade, with surveillance recommended for nondysplastic BE and endoscopic eradication therapy recommended for dysplasia and early neoplasia. Endoscopic resection combined with ablation achieves durable eradication with esophageal preservation.
Zitieren
APA
Rajagopal, G. M., Ravee, A., & Wadhwa, N. (2026). Advances in Barrett’s Esophagus: Screening, Surveillance, and Endoscopic Eradication Strategies. Digestive Disease Interventions. https://doi.org/10.1055/a-2879-9369
Vancouver
Rajagopal GM, Ravee A, Wadhwa N. Advances in Barrett’s Esophagus: Screening, Surveillance, and Endoscopic Eradication Strategies. Digestive Disease Interventions. 2026. doi:10.1055/a-2879-9369
BibTeX
@article{Rajagopal2026,
author = {Rajagopal, Geethanjali M. and Ravee, Anjali and Wadhwa, Neha},
title = {Advances in Barrett’s Esophagus: Screening, Surveillance, and Endoscopic Eradication Strategies},
journal = {Digestive Disease Interventions},
year = {2026},
doi = {10.1055/a-2879-9369}
}
EUVIMED